In Caraco Pharm.
Labs., Ltd. v. Novo Nordisk A/S, 132 S. Ct. 1670 (April 17, 2012) [enhanced version available to lexis.com subscribers],
the Supreme Court unanimously held that a generic drug company may use a
counterclaim provision of the Hatch-Waxman Act to seek correction of an overly
broad use code submitted by a brand drug company in connection with patents listed
in the FDA Orange Book. In this Analysis, Dianna Goldenson El Hioum addresses
this issue and its implications.
Sign in with your Lexis.com ID to access the full text of
this article (approx. 4 pages).
Click here to order the full
text of this article if you do not have a Lexis.com ID
Sign in with your Lexis.com ID to access Patent Law resources on Lexis.com or any of these Mathew Bender Patent Law publications.
Click here to order Patent Law treatises/resources and Mathew Bender publications.
View the LexisNexis
Catalog of Legal and Professional Publications
here for a list of available LexisNexis eBooks.
Click here to learn more about
For more information about LexisNexis products and solutions connect with us through our corporate site.